China's medical products administrator approved Nanjing King-Friend Biochemical Pharmaceutical's (SHA:603707) drug registration for its fulvestrant injection for breast cancer, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug is indicated for post-menopausal estrogen-receptor-positive locally advanced or metastatic breast cancer that relapses following or during anti-estrogen adjuvant therapy, the filing said.
The injection is used simultaneously with abemaciclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer, among other types, the filing said.
Shares closed 2% higher during Tuesday's afternoon trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。